Terms: = Lymphoma AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169
448 results:
1. ezh2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent ezh2 inhibitors for the treatment of B-cell lymphomas.
Wu D; Zeng X; Zhao Y; Qin M; Gong P
Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
[TBL] [Abstract] [Full Text] [Related]
3. Unlocking adult T-cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition.
Tavakoli Shirazi P; Bywater MJ
Immunol Cell Biol; 2024; 102(5):298-301. PubMed ID: 38606590
[TBL] [Abstract] [Full Text] [Related]
4. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract] [Full Text] [Related]
5. TP53 mutation is frequent in mantle cell lymphoma with ezh2 expression and have dismal outcome when both are present.
Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
[TBL] [Abstract] [Full Text] [Related]
6. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
7. A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of ezh2 inhibition.
Falkenstern L; Georgi V; Bunse S; Badock V; Husemann M; Roehn U; Stellfeld T; Fitzgerald M; Ferrara S; Stöckigt D; Stresemann C; Hartung IV; Fernández-Montalván A
Sci Rep; 2024 Jan; 14(1):1739. PubMed ID: 38242973
[TBL] [Abstract] [Full Text] [Related]
8. BMP-ACVR1 Axis is Critical for Efficacy of PRC2 Inhibitors in B-Cell lymphoma.
Liu D; Li Z; Tan D; An Y; Chu L; Chen T; Li W; Zhou A; Xiang R; Zhang L; Qu Y; Qi W
Adv Sci (Weinh); 2024 Mar; 11(12):e2306499. PubMed ID: 38229201
[TBL] [Abstract] [Full Text] [Related]
9. Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell lymphoma: Data from the First-in-Human Phase I Study.
Song Y; Jin Z; Li ZM; Liu Y; Li L; He C; Su H; Zhou H; Li K; Hao S; Zuo X; Wu J; Li D; Wu M; Sun X; Qi J; Cai Z; Li Z; Li Y; Huang Y; Shen J; Xiao Z; Zhu J
Clin Cancer Res; 2024 Apr; 30(7):1248-1255. PubMed ID: 38190117
[TBL] [Abstract] [Full Text] [Related]
10.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
11. Performance of the cobas ezh2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
Shyu JY; Schlag PA; Karwowska SM; Manohar CF; Truong HM; Longshore JW; Zhang G
PLoS One; 2023; 18(12):e0292251. PubMed ID: 38096164
[TBL] [Abstract] [Full Text] [Related]
12. Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell lymphoma by Targeted Gene Sequencing.
Sharma A; Das A; Bal A; Srinivasan R; Malhotra P; Prakash G; Kumar R
Cytogenet Genome Res; 2023; 163(5-6):279-289. PubMed ID: 38071955
[TBL] [Abstract] [Full Text] [Related]
13. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
14. ezh2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma.
Li B; Zhou Q; Wan Q; Qiao X; Chen S; Zhou J; Wuxiao Z; Luo L; Ng SB; Li J; Chng WJ
Clin Epigenetics; 2023 Nov; 15(1):187. PubMed ID: 38031139
[TBL] [Abstract] [Full Text] [Related]
15. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis.
Sato S; Ishii M; Tachibana K; Furukawa Y; Toyota T; Kinoshita S; Azusawa Y; Ando J; Ando M
Exp Hematol; 2024 Feb; 130():104132. PubMed ID: 38029851
[TBL] [Abstract] [Full Text] [Related]
16. Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p.
Lu S; Zeng L; Mo G; Lei D; Li Y; Ou G; Wu H; Sun J; Rong C; He S; Zhong D; Ke Q; Zhang Q; Tan X; Cen H; Xie X; Liao C
PLoS One; 2023; 18(11):e0294729. PubMed ID: 37988356
[TBL] [Abstract] [Full Text] [Related]
17. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (ezh2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract] [Full Text] [Related]
18. Synchronous T-lymphoblastic lymphoma and neuroblastoma in a 3-yr-old with novel germline
Tibout P; Livingston J; Kanwar N; Yuki KE; Shlien A; Ngan B; Irwin MS; Morgenstern DA; Hitzler J; Villani A; Cohen-Gogo S
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37932047
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive genomic profiling reveals molecular subsets of
Johnson SM; Haberberger J; Galeotti J; Ramkissoon L; Coombs CC; Richardson DR; Foster MC; Duncan D; Montgomery ND; Ferguson NL; Zeidner JF
Leuk Lymphoma; 2024 Feb; 65(2):209-218. PubMed ID: 37921062
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of dihydropyridinone derivative as a covalent ezh2 degrader.
Zhou B; Wang B; Zou F; Mei H; Liu Q; Qi S; Wang W; Jin R; Wang A; Chen Y; Liu F; Wang W; Liu J; Liu Q
Eur J Med Chem; 2023 Dec; 261():115825. PubMed ID: 37826933
[TBL] [Abstract] [Full Text] [Related]
[Next]
